Medical Doctor Program year 2025 Source: CMS Open Payments, 2026 publication

Janet Wozniak

Child & Adolescent Psychiatry Boston, MA Medical Doctor

NPI 1619956984 CMS profile 27557

55 Fruit St, Massachusetts General Hospital, Boston, MA 02114

Open in the dashboard

General payments

$8,347

11 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Janet Wozniak of Boston, MA is reported in the CMS Open Payments database as having received $8,347 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $8,347 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janet Wozniak
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Janet Wozniak were reported at $8,347. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Janet Wozniak Child & Adolescent Psychiatry median Middle half National median
2019 $0 $129 $42–$419 $163
2020 $0 $81 $28–$226 $114
2021 $0 $115 $31–$326 $132
2022 $0 $124 $40–$382 $149
2023 $0 $130 $45–$420 $160
2024 $0 $141 $42–$490 $164
2025 $8,347 $132 $41–$474 $169

Breakdown

Who paid General payments · program year 2025
  1. E.R. Squibb & Sons, L.L.C. $8,347 11 payments

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Consulting Fee $6,625 1 payment
  2. Travel and Lodging $1,438 5 payments
  3. Food and Beverage $284 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

236

Median for Psychiatry: 574

Drug cost

$26,224

Median for Psychiatry: $27,624

Branded share of claims

17.8%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lurasidone Hcl Generic 12 $15,053
Buspirone Hcl Generic 34 $2,356
Chlorpromazine Hcl Generic 13 $2,183
Aripiprazole Generic 12 $2,116
Quetiapine Fumarate Generic 30 $1,345
Depakote Er Divalproex Sodium Brand 11 $1,285
Divalproex Sodium Er Divalproex Sodium Brand 31 $719
Lamotrigine Generic 12 $400
Clonazepam Generic 45 $371
Memantine Hcl Generic 11 $222

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record